In the group that received the combined treatment, we distinguished between animals that had progressing tumors and animals with complete tumor remissions to investigate whether the frequency of Adpgk-specific CD8 T cells is indeed positively correlated with a therapeutic benefit (Fig. 6c, right panel). The gene discussed is CD8A; the disease is neoplasm.